aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
DermaSensor, founded in Miami, is a health technology company dedicated to enhancing skin cancer detection. Its core mission is to empower primary care providers with advanced tools for efficient skin cancer evaluations. The company offers an AI-powered medical device designed to detect all three common types of skin cancer, providing immediate and accurate results. Initially launched in Australia in 2021, the product has received CE Marking and recently gained FDA clearance, making it available for sale in the United States.
Notable figures associated with DermaSensor include its team of healthcare and technology experts who have driven the company's innovative approach. The company has garnered significant attention and investment due to its potential to revolutionize skin cancer diagnostics. Key achievements include successful commercial pilots and regulatory approvals, underscoring its impact on improving early skin cancer detection. DermaSensor's technology represents a significant advancement in medical diagnostics, offering a data-driven solution that enhances patient outcomes and supports healthcare providers globally.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Medical Device
Technology
AI
Tags
Healthtech
Model Types
Hardware
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was DermaSensor founded?
DermaSensor was founded in 2009.
Where is DermaSensor's headquarters located?
DermaSensor's headquarters is located in Wilmington, DE, US.
When was DermaSensor's last funding round?
DermaSensor's most recent funding round was for $10M (USD) in June 2022.
How many employees does DermaSensor have?
DermaSensor has 23 employees as of Feb 5, 2024.
How much has DermaSensor raised to-date?
As of July 05, 2023, DermaSensor has raised a total of $27M (USD) since Jun 15, 2022.
Add Comparison
Total Raised to Date
$27M
USD
Last Update Jun 15, 2022
Last Deal Details
$10M
USD
Jun 15, 2022
Series A
Total Employees Over Time
23
As of Feb 2024
DermaSensor Address
251 Little Falls Drive
Wilmington,
Delaware
19808
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts